Skip to content
Start Your Quest
Uncategorized

NRNP 6635 Major Depressive Disorder Case Study

6 min read

Major depressive disorder (MDD) is one of the most common presentations in NRNP 6635 comprehensive psychiatric evaluations. This case study walks through an MDD evaluation, from key findings to differential diagnoses and an evidence-based plan, so you can see how each section of the evaluation fits together.

Quick answer

For MDD, document at least five DSM-5-TR symptoms during the same two-week period, including depressed mood or loss of interest, with distress or impairment. Rule out bipolar disorder, substance-induced and medical causes, assess suicide risk with a structured tool, quantify severity with the PHQ-9 and recommend psychotherapy, antidepressant medication or both with close follow-up.

The patient in this guide is fictional and is used for study purposes only. Diagnostic criteria are summarized in our own words; consult the DSM-5-TR directly for exact criteria, and base your evaluation on your assigned case.

The Case

Case summary

Fictional case: M.R., a 34-year-old woman, presents with three months of low mood after losing her job. She reports, “I can’t sleep and I feel like I’m failing at everything.” She describes anhedonia, early-morning waking, poor appetite with an 8-lb weight loss, fatigue, poor concentration and excessive guilt. She endorses passive death wishes without intent or plan. She denies past periods of elevated mood, decreased need for sleep or risky behavior. Alcohol: 2 glasses of wine weekly. PHQ-9: 18. TSH pending. MSE: psychomotor slowing, soft speech, constricted tearful affect, linear thought process, no psychosis, fair insight and judgment.

DSM-5-TR Criteria (Summarized)

A major depressive episode requires five or more of nine symptoms during the same two-week period, representing a change from previous functioning, with at least one symptom being depressed mood or loss of interest or pleasure. Symptoms must cause clinically significant distress or impairment and not be attributable to a substance or another medical condition, and MDD requires that there has never been a manic or hypomanic episode (American Psychiatric Association, 2022).

SymptomM.R.
Depressed moodYes
AnhedoniaYes
Weight or appetite changeYes (8-lb loss)
Insomnia or hypersomniaYes (early waking)
Psychomotor changeYes (observed slowing)
FatigueYes
Worthlessness or guiltYes
Poor concentrationYes
Thoughts of death or suicidePassive death wishes

Differential Diagnoses

  1. Major depressive disorder, single episode, moderate to severe: criteria met for three months with impairment.
  2. Bipolar II disorder: must be ruled out because antidepressant monotherapy can be risky; screen with the Mood Disorder Questionnaire and obtain collateral history (Hirschfeld et al., 2000). See bipolar disorder psychiatric evaluation.
  3. Depressive disorder due to another medical condition (hypothyroidism): rule out with TSH.

Adjustment disorder with depressed mood is also worth mentioning, but it does not apply when full criteria for MDD are met.

Risk Assessment

Use the C-SSRS to assess ideation, intent, plan and behavior (Posner et al., 2011). Document protective factors and create a collaborative safety plan with crisis resources, including the 988 Suicide & Crisis Lifeline.

Treatment Plan

  • Psychotherapy: evidence-based options include cognitive behavioral therapy, interpersonal therapy and behavioral activation (U.S. Department of Veterans Affairs & U.S. Department of Defense [VA/DoD], 2022).
  • Pharmacotherapy: first-line options include SSRIs, SNRIs, bupropion and mirtazapine, selected by side effect profile, comorbidities, prior response and patient preference (VA/DoD, 2022).
  • Monitoring: follow up within 2–4 weeks, monitor for side effects and emergent suicidality (antidepressants carry a boxed warning for patients up to age 24) and repeat the PHQ-9 to track response (Kroenke et al., 2001).
  • Education and SDOH: explain the expected time to response, address job loss and insurance barriers and connect her with community resources.

Frequently Asked Questions

What is the minimum duration for MDD?

At least two weeks of symptoms for a major depressive episode, according to DSM-5-TR.

Why rule out bipolar disorder before treating depression?

Antidepressant monotherapy in bipolar disorder may trigger mood switching or destabilization, so screening and collateral history are important.

How is depression severity measured?

Tools such as the PHQ-9 quantify severity and track response over time.

Get Help With Your MDD Case Study at Collepals

Comprehensive psychiatric evaluations take time, and NRNP 6635 often requires a new one every few weeks. Collepals.com supports PMHNP students with:

  • Guidance on organizing your case into the comprehensive psychiatric evaluation template.
  • Help comparing DSM-5-TR criteria and building three well-supported differential diagnoses.
  • Current, evidence-based references formatted in APA 7.
  • Model evaluations, case presentations and reflections you can study, plus editing and proofreading of your drafts.

Browse our free model assignments or learn more about our nursing assignment writing service.

Get NRNP 6635 help at Collepals.com

Use Collepals examples as study guides and follow your university’s academic integrity and AI policies when you submit your own work.

More NRNP 6635 study guides

  • NRNP 6635 Comprehensive Psychiatric Evaluation: Complete Guide
  • How to Develop Three Differential Diagnoses in Psychiatric Evaluations
  • How to Compare DSM-5-TR Criteria in Psychiatric Case Studies
  • NRNP 6635 Bipolar Disorder Psychiatric Evaluation
  • How to Develop a Psychiatric Treatment Plan Using DSM-5-TR

Collepals is an independent study resource and is not affiliated with or endorsed by Walden University. Course requirements, templates and rubrics change; always follow your current syllabus and course template. This article is educational and is not clinical advice for any individual patient.

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Jr., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., Russell, J. M., Sachs, G. S., & Zajecka, J. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873

Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x

Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., & Mann, J. J. (2011). The Columbia–Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168(12), 1266–1277. https://doi.org/10.1176/appi.ajp.2011.10111704

U.S. Department of Veterans Affairs & U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the management of major depressive disorder (Version 4.0). https://www.healthquality.va.gov/guidelines/MH/mdd/

Academic Writer & Editor
WhatsApp